

ED

FINANCIAL EXPRESS

XXIV

## TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019  
 Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com  
 CIN : L74999RJ1992PLC013387

Statement Of Standalone Unaudited Financial Results For The Quarter And Year Ended 31st March 2019  
 (Rs. IN LAKHS) except for EPS

Reviewed by  
 respective  
 figures  
 year to  
 view.  
 the Board  
 Limited  
 Lal Baid  
 Director  
 07060481

OR THE

In lakhs

Ended

31/03/18

(Audited)

341.74

6.03

6.03

4.45

5870.60

109.45

70.00

Committee

30, 2019.

and year

33 of the

2015. The

available

company's

Comprehensive

Banking

are the

and the

year.

Directors

Paliwal

6878483

S. No.	Particulars	STANDALONE				
		Quarter Ended		Year Ended		
		31.03.2019	30.12.2018	31.03.2018	31.03.2019	31.03.2018
		AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED
1	Total Income from Operations (Net)	1,560.17	1,359.27	1,417.89	5,889.18	5,597.57
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	96.22	112.93	100.53	435.58	377.26
3	Net Profit / (Loss) for the period before tax (after exceptional and/or extraordinary items)	96.22	112.93	100.53	435.58	377.26
4	Net Profit / (Loss) for the period after tax (after exceptional and / or extraordinary items)	63.22	61.23	73.31	308.04	240.14
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	72.83	61.23	73.31	317.65	240.14
6	Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)	826.37	826.37	773.87	826.37	773.87
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	2,339.54	1,654.39
8	Earning Per Share (of INR 10/- each)					
	(a) Basic	0.77	0.98	0.95	3.73	3.10
	(b) Diluted	0.77	0.98	0.95	3.73	3.10

Statement Of Consolidated Audited Financial Results For The Quarter And Year Ended 31st March 2019  
 (Rs. IN LAKHS) except for EPS

S. No.	Particulars	CONSOLIDATED				
		Quarter Ended		Year Ended		
		31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018
		AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED
1	Total Income from Operations (Net)	1751.30	1503.78	1508.51	6559.45	5782.04
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	109.44	137.81	116.32	554.41	409.96
3	Net Profit / (Loss) for the period before tax (after exceptional and / or extraordinary items)	109.44	137.81	116.32	554.41	409.96
4	Net Profit / (Loss) for the period after tax (after exceptional and / or extraordinary items)	68.26	99.67	88.26	391.23	266.80
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	78.04	99.67	88.26	401.01	266.80
6	Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)	826.37	826.37	773.87	826.37	773.87
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	2,391.26	1,661.83
8	Earning Per Share (of INR 10/- each)					
	(a) Basic	0.80	1.10	1.05	4.26	3.29
	(b) Diluted	0.80	1.10	1.05	4.26	3.29

## Note:

- The above is an extract of the detailed format of consolidated Financial Results for the quarter & year ended 31st March, 2019 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Consolidated Financial Results for the said quarter & year ended 31st March 2019 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above audited financial results for the quarter and year ended 31.03.2019 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on May 29, 2019. The Statutory Auditor have conducted the audit of the financial statements and have expressed an unqualified audit opinion.
- The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) specified in the companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

For and on behalf of Board of Directors  
 for TITAN BIOTECH LIMITED  
 Sd/-  
 NARESH KUMAR SINGLA  
 Managing Director

Place : Delhi  
 Dated : 29.05.2019